Finance

Lists
Why is ELIC up 2,51%?
Dive Deeper
ELIC:STO
Elicera Therapeutics AB
SEK 2,86
+2,51%
(+0,070) 1D
2 āš•.āšĨ., 17 āŧ‚āšĄāš‡ 29 āš™āšēāš—āšĩ 49 āš§āšīāš™āšēāš—āšĩ GMT+2  ·   SEK
All symbols
SymbolPriceChange% Change
Generating top insights for ELIC...
Open
SEK 2,78
High
SEK 2,86
Low
SEK 2,75
Mkt. cap
190,53 āšĨāŧ‰āšēāš™
Avg. vol.
287,70Â āšžāšąāš™
Volume
0,00
52-wk high
SEK 8,21
52-wk low
SEK 2,24
EPS
SEK-0,35
Shares outstanding
66,74 āšĨāŧ‰āšēāš™
No. of employees
3
Open
SEK 2,78
High
SEK 2,86
Low
SEK 2,75
Mkt. cap
190,53 āšĨāŧ‰āšēāš™
Avg. vol.
287,70Â āšžāšąāš™
Volume
0,00
52-wk high
SEK 8,21
52-wk low
SEK 2,24
EPS
SEK-0,35
Shares outstanding
66,74 āšĨāŧ‰āšēāš™
No. of employees
3
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
15 āš™āšēāš—āšĩāšāŧˆāš­āš™
What Ramaco Resources Holders Had To Sit Through
TradingView
TradingView
·
1 āšŠāšŧāŧˆāš§āŧ‚āšĄāš‡āšāŧˆāš­āš™
AI spending to drive another strong S&P 500 earnings season, Goldman Sachs says
AOL.com
AOL.com
·
5 āšŠāšŧāŧˆāš§āŧ‚āšĄāš‡āšāŧˆāš­āš™
History Says Stocks Typically Fall After a Fed Hike Cycle Begins -- Then Gain 6.8% Within a Year. Here's My Plan.
About Elicera Therapeutics AB
CEO-
Employees3
Founded2014
Headquarters-
SectorBiotechnology
Previous reportsAll values in SEK
Loading Previous Earnings...
Revenue
Net income
All values in SEK
āš.āš. 2025
āš—.āš§. 2025
āšĄ.āš™. 2026
āšĄāšī.āš–. 2026
Revenue
7,91 āšĨāŧ‰āšēāš™
30,00Â āšžāšąāš™
-
-147,66Â āšžāšąāš™
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,76 āšĨāŧ‰āšēāš™
7,16 āšĨāŧ‰āšēāš™
5,12 āšĨāŧ‰āšēāš™
6,16 āšĨāŧ‰āšēāš™
Operating expense
7,76 āšĨāŧ‰āšēāš™
7,16 āšĨāŧ‰āšēāš™
5,12 āšĨāŧ‰āšēāš™
6,16 āšĨāŧ‰āšēāš™
Total operating expenses
7,76 āšĨāŧ‰āšēāš™
7,16 āšĨāŧ‰āšēāš™
5,12 āšĨāŧ‰āšēāš™
6,16 āšĨāŧ‰āšēāš™
Operating income
146,69Â āšžāšąāš™
-7,13 āšĨāŧ‰āšēāš™
-5,12 āšĨāŧ‰āšēāš™
-6,31 āšĨāŧ‰āšēāš™
Other non operating income
1,32Â āšžāšąāš™
-
-
-4,00Â āšžāšąāš™
EBT including unusual items
304,15Â āšžāšąāš™
-6,97 āšĨāŧ‰āšēāš™
-5,06 āšĨāŧ‰āšēāš™
-6,26 āšĨāŧ‰āšēāš™
EBT excluding unusual items
304,15Â āšžāšąāš™
-6,97 āšĨāŧ‰āšēāš™
-5,06 āšĨāŧ‰āšēāš™
-6,26 āšĨāŧ‰āšēāš™
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
304,15Â āšžāšąāš™
-6,97 āšĨāŧ‰āšēāš™
-5,06 āšĨāŧ‰āšēāš™
-6,26 āšĨāŧ‰āšēāš™
Net profit margin
3,85%
-23.219,94%
-
4.240,78%
Earnings per share
-
-
-
-
Interest and investment income
156,14Â āšžāšąāš™
169,41Â āšžāšąāš™
61,50Â āšžāšąāš™
47,75Â āšžāšąāš™
Interest expense
-
-5,07Â āšžāšąāš™
-4,78Â āšžāšąāš™
-45,00
Net interest expenses
156,14Â āšžāšąāš™
164,34Â āšžāšąāš™
56,72Â āšžāšąāš™
47,71Â āšžāšąāš™
Depreciation and amortization charges
-
-
-
-
EBITDA
149,63Â āšžāšąāš™
-7,13 āšĨāŧ‰āšēāš™
-
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
āŧāš­āšąāššāš‚āš­āš‡ Google